Business Wire | Mar 8, 2021 05:44PM EST

DiaMedica Therapeutics to Participate at Upcoming Investor Conferences

Mar. 08, 2021

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 08, 2021--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the company's participation are as follows:

* 33rd Annual Roth Conference Details: DiaMedica Therapeutics management will deliver a fireside chat and participate in 1-on-1 meetings Company conference participation date: March 15th, 2021

* Oppenheimer's 31st Annual Healthcare Conference Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings Company conference participation date: March 16th, 2021

* Maxim's Emerging Growth Conference Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings Company conference participation date: March 17th, 2021

For more information or to schedule a one-on-one meeting with management, please contact your conference representative.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, please visit www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005912/en/

CONTACT: Scott Kellen Chief Financial Officer Phone: (763) 496-5118 skellen@diamedica.com